Profund Advisors LLC Purchases 30,456 Shares of Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• Profund Advisors increased its Supernus Pharmaceuticals stake by 351.2% in the third quarter, purchasing 30,456 additional shares and bringing its total position to 39,129 shares valued at approximately $1.68 million.
• Analyst sentiment remains cautious, with Supernus carrying a consensus rating of “Reduce” and an average price target of $62.33. Recent ratings included downgrades from Wall Street Zen and Zacks Research, while Cantor Fitzgerald raised its target to $67.
• Supernus reported third-quarter revenue growth of 18% year over year to $208.6 million, but missed earnings and revenue estimates. The company also announced a special dividend of $8.13 per share, payable November 6 to shareholders of record October 30.

Profund Advisors LLC raised its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 351.2% during the third quarter, according to its most recent filing with the SEC. The firm owned 39,129 shares of the specialty pharmaceutical company's stock after purchasing an additional 30,456 shares during the period. Profund Advisors LLC owned 0.07% of Supernus Pharmaceuticals worth $1,684,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. ProShare Advisors LLC lifted its holdings in Supernus Pharmaceuticals by 78.3% in the third quarter. ProShare Advisors LLC now owns 17,717 shares of the specialty pharmaceutical company's stock valued at $763,000 after buying an additional 7,781 shares during the period. Vise Technologies Inc. bought a new stake in Supernus Pharmaceuticals during the third quarter valued at $249,000. Choreo LLC boosted its position in Supernus Pharmaceuticals by 13.2% during the third quarter. Choreo LLC now owns 12,375 shares of the specialty pharmaceutical company's stock valued at $533,000 after acquiring an additional 1,439 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Supernus Pharmaceuticals by 14.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,606 shares of the specialty pharmaceutical company's stock worth $466,000 after acquiring an additional 1,369 shares during the period. Finally, Signaturefd LLC grew its holdings in Supernus Pharmaceuticals by 12,566.8% during the 3rd quarter. Signaturefd LLC now owns 66,754 shares of the specialty pharmaceutical company's stock worth $2,873,000 after acquiring an additional 66,227 shares during the period.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on SUPN shares. Weiss Ratings lowered Supernus Pharmaceuticals from a "sell (d+)" rating to a "sell (d-)" rating in a research report on Friday. Cantor Fitzgerald upped their target price on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an "overweight" rating in a research report on Thursday, July 9th. Wall Street Zen cut Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. Finally, Zacks Research cut Supernus Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research note on Monday, October 5th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Reduce" and an average target price of $62.33.

Supernus Pharmaceuticals Price Performance

Shares of NASDAQ SUPN opened at $41.92 on Tuesday. The firm has a market cap of $2.44 billion, a PE ratio of -54.44, a P/E/G ratio of 1.21 and a beta of 0.55. The company's fifty day simple moving average is $42.42 and its 200 day simple moving average is $47.27. Supernus Pharmaceuticals, Inc. has a 12-month low of $37.54 and a 12-month high of $59.68.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The specialty pharmaceutical company reported $0.35 earnings per share for the quarter, missing the consensus estimate of $0.49 by ($0.14). Supernus Pharmaceuticals had a negative net margin of 13.23% and a positive return on equity of 11.13%. The company had revenue of $208.60 million during the quarter, compared to the consensus estimate of $217.56 million. During the same period last year, the firm posted ($0.80) earnings per share. The company's revenue for the quarter was up 18.0% on a year-over-year basis. On average, equities analysts predict that Supernus Pharmaceuticals, Inc. will post 1.79 earnings per share for the current year.

Supernus Pharmaceuticals Dividend Announcement

The company also recently announced a special dividend, which will be paid on Friday, November 6th. Investors of record on Friday, October 30th will be given a $8.13 dividend.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for disorders of the central nervous system. The company's activities center on epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological conditions, with an emphasis on products designed to provide differentiated dosing or delivery characteristics.

Supernus' marketed products include Trokendi XR (topiramate extended-release) for the prevention of migraine headaches and the treatment of certain seizure disorders, Oxtellar XR (oxcarbazepine extended-release) for partial-onset seizures, and Qelbree (viloxazine extended-release) for ADHD in patients six years of age and older.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.